Reports Q4 revenue $22.8M, consensus $44.64M. “We continue to progress our flagship rare disease programs and look forward to sharing ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

As Rare Disease Day is commemorated on 28 February, experts discuss the barriers to gene therapy access for some rare ...

Factor II deficiency is a rare bleeding disorder. Symptoms can vary from mild to severe. It may be inherited or a result of other factors, such as medication disease or an autoimmune response.

Vitamin K deficiency is rare. This vitamin is made naturally by bacteria in the gut and is found in several food sources, namely leafy green vegetables and vegetable oils. Not getting enough vitamin K ...

A dopamine deficiency may have links to several medical conditions, including depression, Parkinson’s disease, and attention deficit hyperactivity disorder (ADHD). Dopamine is a neurotransmitter ...

Vitamin deficiency due to hair loss (alopecia) may occur with deficiencies in vitamins B, D, C, and E, as well as with certain minerals like iron, selenium, and zinc. The complex roles of nutritional ...

Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs ...

2. ARCT-810 for Ornithine Transcarbamylase (OTC) deficiency: The US Phase 2 study (NCT06488313) involves dosing at 0.5 mg/kg over an 85-day period, also assessing adverse events as the primary ...